Answers are grounded in this paper and cite their sources.
Pulmonary embolism can masquerade as STEMI and ventricular tachycardia, and potential drug interactions reducing DOAC bioavailability must be considered in patients on complex regimens.
A middle-aged man with metastatic lung adenocarcinoma presented with acute dyspnoea and chest tightness, triggering a primary percutaneous coronary intervention alert for suspected myocardial infarction. He had a left-sided deep vein thrombosis diagnosed 1 week prior, treated with rivaroxaban and was on day 3 of entrectinib chemotherapy for lung cancer. Examination revealed haemodynamic compromise. Electrocardiography revealed widespread ST elevation (V2-V6, II, III, aVF), but coronary angiography showed unobstructed coronary arteries. Echocardiography and elevated troponin levels suggested right ventricular strain, prompting CT pulmonary angiography, which confirmed pulmonary embolism. He required intensive care unit admission, oxygen supplementation and vasopressors. Subsequently, he developed sustained ventricular tachycardia, managed with an amiodarone infusion. Rivaroxaban was switched to intravenous unfractionated heparin. This case highlights pulmonary embolism (PE) occurring despite therapeutic anticoagulation, suggesting direct oral anticoagulant failure, possibly due to entrectinib reducing rivaroxaban bioavailability. It also demonstrates PE mimicking ST-elevation myocardial infarction and VT in a high-risk patient.
No takes yet. Share an insight, caveat, or question.
May Honey Ohn (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: